Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,928 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Pressure, High Clear all
Active, not recruiting Not applicable Interventional

Community Engagement Alliance Against Disparities

NCT06607341
View directory record Official record
Conditions
Diabetes, Pre-diabetes, Hypertension, Overweight and Obesity
Interventions
Multi-level, community-digital health promotion intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

NCT00601302
View directory record Official record
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 14, 2026, 1:14 PM EDT
Terminated Phase 4 Interventional Results available

Crossover Study From Macitentan or Bosentan Over to Ambrisentan

NCT02885012
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
New Orleans, Louisiana • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 14, 2026, 1:14 PM EDT
Completed No phase listed Observational Results available

Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow

NCT01308788
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tri Staple Technology Stapler Used in Gastric Bypass

NCT01026103
View directory record Official record
Conditions
Sleep Apnea, Hypertension, Hyperlipidemia, Coronary Artery Disease, Gastroesophageal Reflux Disease, Osteoarthritis, Diabetes
Interventions
Tri Staple Technology stapler
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Not applicable Interventional

MyLife: A Digital Health Coaching Program

NCT03529903
View directory record Official record
Conditions
Lifestyle-related Condition, Obesity, Sedentary Lifestyle, PreDiabetes, Hypertension
Interventions
Health Coaching
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Phase 2 Interventional

Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate

NCT03234361
View directory record Official record
Conditions
Hypertension
Interventions
High Phosphate Phase, Low Phosphate Phase
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 14, 2026, 1:14 PM EDT
Not listed Not applicable Interventional

Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical Problems

NCT02868983
View directory record Official record
Conditions
Arthritis, Asthma, Chronic Obstructive Lung Disease, Diabetes, Heart Failure, Hypertension, Anxiety, Chronic Pain, Depression, Fibromyalgia, Insomnia, Irritable Bowel Syndrome, Problem Drinking, Substance Use Disorder
Interventions
Integration
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
4,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 14, 2026, 1:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Polypill for Prevention of Cardiomyopathy

NCT06143566
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure
Interventions
Polypill, Combined prescription of the individual medications
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives

NCT02757872
View directory record Official record
Conditions
Hypertension, Kidney Diseases
Interventions
Vitamin D3, Omega-3 Fatty acids, Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
50 Years to 99 Years
Enrollment
2,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

NCT01254370
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Ocular Surface Disease
Interventions
Latanoprost, Travatan Z
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

NCT00477269
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib mesylate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905
View directory record Official record
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Not applicable Interventional

Peau o le Vasa: Analysis of the Efficacy and Feasibility of the PILI Lifestyle Program (PLP) + Social Determinants of Health (SDOH) Intervention and Adaptation of SDOH Measures Pilot Study

NCT06471595
View directory record Official record
Conditions
Weight Loss Trial, Cardiometabolic Syndrome, Hypertension, Dyslipidemia, Pre-diabetes, Type 2 Diabetes Mellitus
Interventions
Partnership for Improving Lifestyle Intervention (PILI) Lifestyle Program + Social Determinants of Health (SDOH) Component
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Fayetteville, Arkansas • Springdale, Arkansas • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 14, 2026, 1:14 PM EDT
Withdrawn Early Phase 1 Interventional

Impedance Cardiography to Decrease the Risk of Preeclampsia

NCT03245970
View directory record Official record
Conditions
Chronic Hypertension Complicating Pregnancy (Diagnosis), Preeclampsia
Interventions
Labetalol Hydrocholoride 200 mg orally every 12 hours, Nifedipine 60 mg orally daily, Atenolol 25 mg daily
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
18 Years to 51 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 14, 2026, 1:14 PM EDT
Withdrawn Phase 4 Interventional

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

NCT00625469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
bosentan
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 14, 2026, 1:14 PM EDT
Terminated Phase 3 Interventional

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

NCT00389675
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
85
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Not applicable Interventional

The CREATE Wellness Study

NCT02302612
View directory record Official record
Conditions
Diabetes, Heart Disease, Hypertension, Dyslipidemia
Interventions
CREATE Wellness, Usual Care Control
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 85 Years
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Not applicable Interventional

Group-based Chronic Kidney Disease Care

NCT02467894
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Group-based Care
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

NCT05128929
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Hymecromone (H01), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does Glaucoma Cause Loss of Brain Function?

NCT01303939
View directory record Official record
Conditions
Glaucoma
Interventions
magnetic resonance imaging (MRI) of the brain
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 14, 2026, 1:14 PM EDT
Recruiting Phase 2 Interventional

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

NCT06104228
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 14, 2026, 1:14 PM EDT
Completed Phase 4 Interventional

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

NCT00239538
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 14, 2026, 1:14 PM EDT